SCHEMBL30718564

SCHEMBL30718564

C[C@@H]1[C@H](OC(=O)c2ccccc2)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
GPR119 Q8TDV5 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
SLC18A3 Q16572 1/20 0.42
USP30 Q70CQ3 2/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
CHRNA7 P36544 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
PIK3CD O00329 1/20 0.41
KLK7 P49862 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13586670 0.84 KDM4E (0.42) MEN1KMT2AKDM4EPKMGPR119
SCHEMBL13651212 0.84 MEN1 (0.51) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL27140174 0.84 MEN1 (0.51) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL2200153 0.84 MAPT (0.48) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL25772120 0.84 MAPT (0.48) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL31321284 0.84 MAPT (0.48) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL30442342 0.84 MAPT (0.48) MEN1KMT2ACHRM2CHRM4CHRM1
SCHEMBL5803431 0.83 KCNH2 (0.46) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2964414 0.83 KCNH2 (0.46) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL5803438 0.83 KCNH2 (0.46) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 MEN1 1699/4885KMT2A 1212/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.